#153393

Anti-Lewis Y [69/229]

Cat. #153393

Anti-Lewis Y [69/229]

Cat. #: 153393

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: Lewis Y

Class: Monoclonal

Application: FACS ; IHC

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Lindy Durrant

Institute: University of Nottingham

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-Lewis Y [69/229]
  • Research fields: Cancer;Genetics
  • Clone: 69/229
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: FACS ; IHC
  • Description: MAbs targeting both Lewis(y) and Lewis(b) may have a therapeutic advantage over mAbs targeting just one hapten. 692/29 has a more restricted normal tissue distribution and a higher antigen threshold for killing which should reduce its toxicity compared to a Lewis(y) specific mAb. 692/29 has an ability to directly kill tumours whereas the anti-Lewis(b) mAb does not. This suggests that Lewis(y) but not Lewis(b) are functional glycans. 692/29 showed good anti-tumour responses in vivo and is a strong therapeutic candidate.
  • Immunogen: Colonic Adenoma membranes
  • Isotype: IgG3 kappa
  • Myeloma used: P3/NS1/1-Ag4.1

Target Details

  • Target: Lewis Y
  • Target background: MAbs targeting both Lewis(y) and Lewis(b) may have a therapeutic advantage over mAbs targeting just one hapten. 692/29 has a more restricted normal tissue distribution and a higher antigen threshold for killing which should reduce its toxicity compared to a Lewis(y) specific mAb. 692/29 has an ability to directly kill tumours whereas the anti-Lewis(b) mAb does not. This suggests that Lewis(y) but not Lewis(b) are Fn glycans. 692/29 showed good anti-tumour responses in vivo and is a strong therapeutic candidate.

Applications

  • Application: FACS ; IHC

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Noble et al. 2013. PLoS One. 8(2):e54892. PMID: 23408949.
  • Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29.